Drug Shortage Report for RIFADIN

Last updated on 2020-07-15 History
Report ID 79314
Drug Identification Number 02092808
Brand name RIFADIN
Common or Proper name Rifadin 300mg
Market Status DORMANT
Active Ingredient(s) RIFAMPIN
Strength(s) 300MG
Dosage form(s) CAPSULE
Route of administration ORAL
Packaging size 100
ATC code J04AB
Reason for shortage Other (Please describe in comments)
Anticipated start date
Actual start date 2019-07-15
Estimated end date Unknown
Actual end date
Shortage status Actual shortage
Updated date 2020-07-15
Company comments July 15th, 2020: Rifadin strengths are in Dormant status The shortage is due to a production delay and an increase in demand. Sanofi is working diligently to make the product available as soon as possible. We are in communication with Health Canada to work towards reducing the duration of the backorder. Sanofi has no supply remaining at its warehouse or at the wholesale level.
Health Canada comments
Company contact information email: CAINTERNET@sanofi.com Telephone: 1-800-265-7927

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v14 2020-07-15 French Compare
v13 2020-07-15 English Compare
v12 2020-01-14 French Compare
v11 2020-01-14 English Compare
v10 2020-01-13 French Compare
v9 2020-01-13 English Compare
v8 2020-01-06 French Compare
v7 2020-01-06 English Compare
v6 2019-07-16 English Compare
v5 2019-03-22 French Compare
v4 2019-03-22 English Compare
v3 2019-03-22 French Compare
v2 2019-03-22 English Compare
v1 2019-03-22 English Compare